How to Get Prolia (Denosumab) in Washington

What Prolia Is and Who It Is For

Prolia is the brand name for denosumab 60 mg given by subcutaneous injection once every six months. The current professional prescribing information in DailyMed lists indications that include certain postmenopausal women and men with osteoporosis at high risk for fracture, glucocorticoid-induced osteoporosis at high risk for fracture, and bone loss associated with specified hormone-ablation therapies.

Diagnosis alone does not guarantee that denosumab is the right first treatment. The clinician considers fracture history, bone density, overall fracture risk, previous osteoporosis drugs, kidney and mineral metabolism, adherence, and the consequences of eventually stopping treatment.

The FREEDOM trial found that denosumab reduced vertebral, hip, and nonvertebral fractures in postmenopausal women with osteoporosis over 36 months (PMID 19671655). That efficacy evidence does not determine an individual Washington insurer’s coverage rules.

A Washington Access Pathway

1. Arrange an Evaluation

A primary-care clinician, endocrinologist, rheumatologist, gynecologist, geriatrician, or other appropriately licensed prescriber can evaluate osteoporosis. A telehealth visit may be useful for history, record review, and planning when the clinician considers remote care appropriate. Telehealth does not eliminate the examination, testing, and administration requirements described in the current label.

Useful records include:

• the most recent DXA report;
• prior fragility fractures and relevant imaging;
• previous osteoporosis medicines, dates, response, and adverse effects;
• current calcium and vitamin D intake;
• kidney history and recent laboratory results;
• dental history and planned invasive dental work; and
• the date of the last denosumab injection, if already receiving it.

2. Complete the Safety Review

Pre-existing hypocalcemia must be corrected before Prolia. The current label directs all patients to receive calcium 1,000 mg daily and at least 400 IU vitamin D daily, unless the treating clinician changes that plan for a specific reason.

The label carries a boxed warning that Prolia increases the risk of severe hypocalcemia in patients with advanced chronic kidney disease, with greater risk in the presence of chronic kidney disease-mineral bone disorder. For those patients, the label calls for evaluation by a clinician experienced in CKD-mineral bone disorder and substantially closer calcium monitoring than a routine osteoporosis visit.

The safety review can include serum calcium, kidney function, and evaluation for vitamin D deficiency or mineral-bone disorder based on the patient’s risk. Neither the FDA label nor Washington policy establishes one universal vitamin D threshold, fixed laboratory panel, or guaranteed result turnaround for every patient.

3. Verify the Benefit and Authorization Route

Denosumab may be processed under a medical benefit when supplied by a clinic or under a pharmacy benefit when obtained through a specialty pharmacy. The route affects authorization, site-of-care rules, and out-of-pocket cost, which is why the current HCA list and member-specific plan information matter.

For Washington Apple Health, start with the Health Care Authority’s current Preferred Drug List. HCA explains that all managed-care and fee-for-service plans use the Apple Health PDL, while additional criteria are identified in the list. A member should also contact the managed-care plan listed on the insurance card because network and administration arrangements can differ.

For Uniform Medical Plan members, HCA publishes current preauthorization criteria for medications covered under the medical benefit. Other commercial plans publish their own medical and pharmacy policies. Criteria can change, so a historical article should not state that every Washington plan requires one failed oral bisphosphonate or promises a particular approval time. The linked UMP document states that its updates are effective July 1, 2026 and that preauthorization requirements may change in later months.

Ask the plan or clinic:

1. Is Prolia reviewed under the medical benefit, pharmacy benefit, or either?
2. Is prior authorization required for this indication?
3. Are there preferred denosumab products or prerequisite therapies?
4. Which clinicians, infusion centers, or pharmacies are in network?
5. Is specialty-pharmacy shipment required, and where may it be sent?
6. What deductible, coinsurance, or copay applies to the drug and administration?

4. Select the Administration Site

The current label says Prolia should be administered by a healthcare provider. Depending on the plan and local network, administration may occur in a clinician’s office, hospital outpatient department, or another authorized site. Home administration should not be assumed; confirm whether it is clinically and contractually available.

Prolia must remain refrigerated at 2°C to 8°C in its original carton. If removed from refrigeration, the label permits storage at room temperature up to 25°C in the original container and requires use within 30 days. Patients should follow the dispensing pharmacy and administration site’s handling instructions rather than arranging informal shipment or storage.

What a Strong Prior-Authorization Submission Contains

Requirements vary, but the following records commonly help the reviewer apply the plan’s own criteria:

• diagnosis and fracture-risk assessment;
• DXA report and relevant fracture imaging;
• prior osteoporosis treatments, including response, intolerance, or contraindication;
• current clinical notes explaining why denosumab was selected;
• laboratory results relevant to safe administration;
• requested product, dose, frequency, and site of care; and
• continuity information for a patient already receiving denosumab.

If authorization is denied, obtain the written reason and the exact plan criterion. A useful appeal responds to that criterion with records or a clinical explanation. Approval timelines, peer-to-peer options, and appeal procedures are plan-specific.

Do Not Miss the Six-Month Continuity Problem

Denosumab’s effect reverses when treatment is delayed or stopped. The current label warns that fracture risk increases after discontinuation, including the risk of multiple vertebral fractures, and directs transition to an alternative antiresorptive therapy if Prolia is discontinued.

A post hoc analysis of FREEDOM and its extension documented vertebral fractures after discontinuation (PMID 29105841). The Bone Health and Osteoporosis Foundation clinician’s guide also emphasizes that skeletal deterioration resumes after osteoporosis medication is stopped and occurs sooner with non-bisphosphonate therapies such as denosumab (PMID 35478046).

For a move, insurance change, or new prescriber, begin coordination before the next dose is due. Transfer the last injection date, DXA report, laboratory results, prior-authorization history, and planned administration site. Do not simply “take a drug holiday” from denosumab.

Dental and Infection Considerations

The label warns about osteonecrosis of the jaw and recommends a routine oral examination before starting. A dental examination with preventive dentistry is recommended for patients with risk factors such as invasive dental procedures, cancer treatment, corticosteroids, poor oral hygiene, or other comorbid disorders.

This does not mean every dental procedure requires stopping Prolia. The prescriber and dentist should weigh the procedure, fracture risk, treatment timing, and the risks of interruption identified in the prescribing information. Serious infections and significant skin reactions also warrant prompt clinical review.

Cost and Assistance

There is no reliable statewide cash price or copay. The amount depends on the product, benefit route, administration site, negotiated rate, deductible, coinsurance, secondary coverage, and eligibility for assistance. Obtain a plan-specific estimate that includes both the drug and administration fee.

Manufacturer assistance and copay programs have eligibility rules and can change. Patients should verify current terms directly with the program and insurer instead of relying on a fixed copay or cash-price estimate.